Neuroendocrine tumors (NETs) are a type of cancerous growth affecting cells that send hormones around the body. Pancreatic neuroendocrine tumors (PNETs) grow in the cells of the pancreas that produce ...
Two distinct subtypes discovered, each with dramatically different risks of recurrence Patients with more aggressive subtype can be monitored vigilantly for recurrence and possible treatment, while ...
Effect of BPM 31510 on survival outcomes when used in combination with gemcitabine in a preclinical model of pancreatic cancer. Serum levels of macrophage inhibitory cytokine-1 (MIC1) and matrix ...
A group of researchers funded by Neuroendocrine Tumor Research Foundation (NETRF) has discovered molecular information that may help predict recurrence of non-functional pancreatic neuroendocrine ...
Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center. Second-line gemcitabine ...
SEATTLE -- Surgery for pancreatic neuroendocrine tumors (pNETs) significantly improved survival for all patients except those with the earliest-stage disease, a retrospective review of 4,700 patients ...
Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery].
SEATTLE -- Patients with small (<1 cm) pancreatic neuroendocrine tumors (pNETs) had a 5-year survival of 100% with surveillance, data from a large retrospective study showed. Surgery for small pNETs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results